type your search, and then press enter

Noticias y Eventos

Descubra las novedades en el campo de las patologías oculares hereditarias

Blog operado por el equipo de DBGen que actualiza terapias, noticias y eventos relacionados con las enfermedades hereditarias oculares. Le invitamos a participar en este foro.

DBGen and the UB-CIBERER U-718 group present their current research in genetic diagnosis and animal models of inherited retinal dystrophies in ARVO 2019

Dr. Gemma Marfany (co-founder and scientific board member of DBGen) presented an oral communication in ARVO 2019 (held in Vancouver, 2-6 May) to show the most prominent results of the research that his group at the UB-CIBERER (U-718) and DBGEN are currently undertaking to study inherited retinal dystrophies. This work is focused on improved genetic diagnosis and the generation of...

read more

Professor Gemma Marfany has been awarded the distinction of the Council of Doctors and the Board of Trustees of the University of Barcelona for her contribution to scientific communication

03/04/19 - DBGen,

Professor Gemma Marfany, co-founder and associate director of DBGen Ocular Genomics, has been honored with the Distinction of the Council of Doctors and the Board of Trustees of the University of Barcelona (UB) in its sixth edition. The award ceremony was held on April 2, 2019, in the Aula Magna of the Historic Building of the UB. With this distinction,...

read more

We celebrate our first anniversary with a summary of the year

20/12/18 - DBGen, Genetic Diagnosis,

In January 2018, Dr. Roser Gonzàlez-Duarte and Dr. Gemma Marfany founded DBGen Ocular Genomics, a spin-off of the University of Barcelona. Their goal was to approach the genetic diagnosis of ocular hereditary diseases with the highest scientific standards. DBGen Ocular Genomics was born from the experience of more than 25 years of research on the genetic and molecular bases of...

read more

RD2018 Congress discloses new advances and upcoming therapies for Retinal Dystrophies

In September 2018 two relevant meetings related to ocular diseases, the RD2018 International Symposium on Retinal Degeneration and the ISER (International Society for Eye Research) Conference, have taken place in Ireland. In particular, the RD2018 meeting, in which the DBGen team presented two contributions, has focused on the latest advances in genetic diagnosis, disease mechanisms and therapeutic approaches of Retinal...

read more

Revolution in Genetic Diagnosis, our contribution to Barraquer magazine

PhD. Roser Gonzàlez and PhD. Gemma Marfany, founders and directors of the company DBGen Ocular Genomics, were invited to participate as columnists of the issue 32 of the Barraquer Ophthalmology Center magazine. Their contribution was dedicated to the genetic diagnosis of inherited eye diseases, emphasizing aspects such as the importance of new technologies: "Massive sequencing of the whole gene or specific genetic regions...

read more

LUXTURNA, made available to European patients by Novartis

Spark Therapeutics enters into a licensing agreement with the big pharmaceutical company Novartis to commercialize LUXTURNA, the first gene therapy treatment approved for inherited retinal dystrophies, in Europe. LUXTURNA is addressed to patients suffering from Leber Congenital Amaurosis (LCA) caused by mutations in the RPE65 gene. This one-time gene therapy consists of a subretinal microinjection of therapeutic adenoassociated virus that...

read more
1 2
Copyright © 2019. All Rights Reserved -